Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma

Table 3 Patient treatment-related adverse events, n (%)

AEs	Any grade	Grade 1	Grade 2	Grade 3
Leukopenia	21 (39.62)	11 (20.75)	10 (18.87)	0
Thrombocytopenia	12 (22.64)	12 (22.64)	0 (0.00)	0
Rash	7 (13.21)	3 (5.66)	4 (7.55)	0
Itchy skin	5 (9.43)	5 (9.43)	0 (0.00)	0
Hand-foot syndrome	17 (32.08)	10 (18.87)	7 (13.21)	0
Increased serum ALT and AST levels	25 (47.17)	23 (43.40)	2 (3.77)	0
Increased serum bilirubin	8 (15.09)	6 (11.32)	2 (3.77)	0
Diarrhea	5 (9.43)	3 (5.66)	2 (3.77)	0
Nausea, vomiting	24 (45.28)	13 (24.53)	11 (20.75)	0
Proteinuria	10 (18.87)	4 (7.55)	6 (11.32)	0
Hypothyroidism	16 (30.19)	0 (0.00)	16 (30.19)	0
Gastrointestinal bleeding	5 (9.43)	0 (0.00)	1 (1.88)	4 (7.55)
Stomachache	17 (32.08)	10 (18.87)	7 (13.21)	0
Hair loss	4 (7.55)	4 (7.55)	0 (0.00)	0
Weight loss	9 (16.98)	9 (16.98)	0 (0.00)	0
Decreased appetite	25 (47.17)	23 (43.40)	2 (3.77)	0
Fatigue	19 (35.85)	19 (35.85)	0 (0.00)	0
Hypertension	24 (45.28)	2 (3.77)	22 (41.51)	0